nintedanib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiogenesis inhibitors 4903 656247-17-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BIBF1120
  • nibtedanib
  • nintedanib
  • nintedanib esylate
  • intedanib
  • BIBF 1120
  • ofev
  • nintedanib ethanesulfonate
  • vargatef
  • Molecular weight: 539.64
  • Formula: C31H33N5O4
  • CLOGP: 3.08
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 94.22
  • ALOGS: -4.24
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.38 g O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.50 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class AAK1,ABL2,ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK4,CDK5,CDK6,CDK7,CDK9,CHEK1,CLK2,CLK4,CSF1R,DDR1,DYRK1A,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB1,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FLT4,FYN,GAK,GRK1,GRK2,GSK3A,GSK3B,IGF1R,IKBKB,INSR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MARK4,MELK,MET,MINK1,MST1R,MTOR,NTRK1,NTRK2,NTRK3,NUAK1,PAK2,PAK4,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PIM3,PRKAA1,PRKAA2,PRKCD,PRKCZ,PRKDC,RIPK3,ROCK1,RPS6KA1,SGK1,SIK2,SIK3,SRC,STK10,STK33,STK4,SYK,TEK,TGFBR1,TNIK,TNK1,TTK,TYRO3,ULK1,ULK2,YES1,ZAP70 138
kinase-selectivity-class AAK1,ABL2,ACVR2A,ACVR2B,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK16,CDK4,CDK6,CDK7,CDK9,CHEK1,CLK2,CLK4,CSF1R,CSK,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FLT4,FYN,GAK,GSK3A,GSK3B,HIPK2,IGF1R,INSR,IRAK1,IRAK3,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K3,MAP2K6,MAP3K10,MAP3K11,MAP3K19,MAP3K2,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK12,MAPK7,MAPK8,MARK1,MARK4,MELK,MET,MINK1,MST1R,MTOR,MYLK,NTRK1,NTRK3,NUAK1,PAK2,PAK4,PDGFRB,PDK1,PDK4,PDPK1,PIM3,PLK4,PRKAA1,PRKAA2,PRKCD,PRKG1,PTK2,RIPK3,SIK2,SIK3,SRC,STK10,STK16,STK33,STK4,SYK,TEK,TNIK,TNK1,TTK,TYRO3,ULK1,ULK2,YES1 113
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 28.184 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.006 % High 1

Approvals:

DateAgencyCompanyOrphan
July 3, 2015 PMDA Boehringer Ingelheim
Oct. 15, 2014 FDA BOEHRINGER INGELHEIM
Nov. 20, 2014 EMA Boehringer Ingelheim International GmbH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1352.02 21.06 1243 16450 937947 89672807
Nausea 397.06 21.06 743 16950 1109573 89501181
Death 366.56 21.06 447 17246 456104 90154650
Decreased appetite 279.79 21.06 355 17338 376185 90234569
Vomiting 265.93 21.06 516 17177 787777 89822977
Malignant neoplasm progression 240.36 21.06 185 17508 106685 90504069
Weight decreased 156.74 21.06 272 17421 379638 90231116
Dyspnoea 134.23 21.06 426 17267 880529 89730225
Cough 131.52 21.06 248 17445 368714 90242040
Disease progression 110.09 21.06 144 17549 156471 90454283
Interstitial lung disease 97.85 21.06 96 17597 76309 90534445
Flatulence 85.06 21.06 68 17625 41299 90569455
Respiratory failure 84.92 21.06 110 17583 118308 90492446
Forced vital capacity decreased 83.17 21.06 23 17670 1155 90609599
Dyspnoea exertional 80.09 21.06 84 17609 72204 90538550
Idiopathic pulmonary fibrosis 75.79 21.06 23 17670 1607 90609147
Oxygen saturation decreased 75.74 21.06 99 17594 107384 90503370
Pulmonary hypertension 75.11 21.06 64 17629 42459 90568295
Constipation 74.37 21.06 167 17526 280228 90330526
Pneumothorax 70.71 21.06 45 17648 19122 90591632
Drug ineffective 69.67 21.06 102 17591 1384196 89226558
Pulmonary embolism 69.16 21.06 105 17588 130715 90480039
Systemic scleroderma 63.65 21.06 20 17673 1569 90609185
Mucosal infection 63.28 21.06 13 17680 176 90610578
Hepatotoxicity 63.19 21.06 60 17633 45782 90564972
Gamma-glutamyltransferase increased 62.73 21.06 55 17638 37897 90572857
Epistaxis 60.88 21.06 79 17614 85046 90525708
Productive cough 55.86 21.06 72 17621 76991 90533763
Infusion related reaction 54.96 21.06 8 17685 416772 90193982
Lung transplant 53.94 21.06 22 17671 3670 90607084
Arthropathy 53.32 21.06 5 17688 366237 90244517
Lung diffusion test decreased 53.07 21.06 15 17678 816 90609938
Maternal exposure during pregnancy 52.20 21.06 5 17688 360058 90250696
Drug hypersensitivity 50.55 21.06 14 17679 463595 90147159
Systemic lupus erythematosus 49.97 21.06 6 17687 361890 90248864
Transaminases increased 49.97 21.06 48 17645 37144 90573610
Joint swelling 49.89 21.06 18 17675 503282 90107472
Abnormal loss of weight 49.65 21.06 25 17668 6798 90603956
Alanine aminotransferase increased 47.64 21.06 84 17609 118254 90492500
Faeces soft 47.39 21.06 25 17668 7486 90603268
Swelling 46.92 21.06 12 17681 419046 90191708
Intestinal haemorrhage 46.78 21.06 21 17672 4426 90606328
Toxicity to various agents 44.48 21.06 3 17690 287843 90322911
Product use issue 44.26 21.06 6 17687 329913 90280841
Treatment failure 42.05 21.06 5 17688 303923 90306831
Hypersensitivity 40.61 21.06 19 17674 454658 90156096
Pulmonary function test decreased 40.32 21.06 19 17674 4475 90606279
Aspartate aminotransferase increased 40.06 21.06 72 17621 102865 90507889
Liver disorder 39.96 21.06 79 17614 121190 90489564
Haemoptysis 39.19 21.06 40 17653 33280 90577474
Hepatic function abnormal 37.93 21.06 46 17647 46242 90564512
Abdominal pain upper 37.40 21.06 146 17547 332528 90278226
Pneumomediastinum 36.30 21.06 14 17679 2017 90608737
Musculoskeletal stiffness 36.18 21.06 7 17686 296525 90314229
Pain 34.69 21.06 91 17602 996250 89614504
Discomfort 34.49 21.06 6 17687 274329 90336425
Drug-induced liver injury 33.65 21.06 62 17631 90256 90520498
COVID-19 33.45 21.06 90 17603 168753 90442001
Pneumatosis intestinalis 32.28 21.06 15 17678 3422 90607332
White blood cell count decreased 32.03 21.06 88 17605 167021 90443733
Confusional state 31.71 21.06 18 17675 386187 90224567
Scleroderma 31.64 21.06 18 17675 6243 90604511
Blister 31.14 21.06 6 17687 254992 90355762
Telangiectasia 30.05 21.06 11 17682 1372 90609382
Liver function test increased 30.05 21.06 57 17636 84798 90525956
Hypoxia 29.91 21.06 52 17641 72347 90538407
Fibromyalgia 29.52 21.06 3 17690 206266 90404488
Arthralgia 29.50 21.06 68 17625 778454 89832300
Acute respiratory failure 29.38 21.06 39 17654 42879 90567875
Large intestine perforation 29.03 21.06 20 17673 9692 90601062
Weight increased 28.32 21.06 24 17669 417903 90192851
Metastases to central nervous system 28.14 21.06 25 17668 17517 90593237
Urticaria 28.01 21.06 13 17680 312721 90298033
Dehydration 27.49 21.06 92 17601 194355 90416399
Diarrhoea haemorrhagic 27.34 21.06 20 17673 10643 90600111
Irritable bowel syndrome 27.28 21.06 4 17689 207444 90403310
KL-6 increased 27.20 21.06 6 17687 116 90610638
Microstomia 27.08 21.06 5 17688 37 90610717
Pneumonitis 27.01 21.06 38 17655 44132 90566622
Pneumonia 26.60 21.06 214 17479 637845 89972909
Neutrophil count decreased 25.26 21.06 48 17645 71484 90539270
Asthma 25.11 21.06 8 17685 242152 90368602
Mobility decreased 24.75 21.06 9 17684 250725 90360029
Rheumatoid arthritis 24.34 21.06 21 17672 362593 90248161
Gastrointestinal necrosis 24.00 21.06 12 17681 3213 90607541
Exercise tolerance decreased 23.63 21.06 16 17677 7535 90603219
Total lung capacity abnormal 22.80 21.06 5 17688 94 90610660
Wheezing 22.74 21.06 9 17684 238071 90372683
Abdominal pain 22.43 21.06 143 17550 395578 90215176
Adenosquamous cell lung cancer 22.39 21.06 4 17689 24 90610730
Impaired healing 22.13 21.06 9 17684 234190 90376564
Fatigue 21.95 21.06 331 17362 1153692 89457062
Sepsis 21.89 21.06 81 17612 179733 90431021
Dermatitis acneiform 21.18 21.06 14 17679 6340 90604414

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1939.93 18.94 1724 20858 459125 42139628
Death 482.17 18.94 876 21706 470309 42128444
Decreased appetite 399.07 18.94 500 22082 192637 42406116
Malignant neoplasm progression 388.30 18.94 375 22207 108025 42490728
Weight decreased 333.72 18.94 476 22106 207472 42391281
Pneumothorax 240.95 18.94 152 22430 23391 42575362
Dyspnoea 202.13 18.94 601 21981 442020 42156733
Lung transplant 176.81 18.94 61 22521 2325 42596428
Cough 157.73 18.94 313 22269 177790 42420963
Nausea 155.11 18.94 511 22071 396288 42202465
Respiratory failure 134.16 18.94 242 22340 127890 42470863
Idiopathic pulmonary fibrosis 118.86 18.94 55 22527 4549 42594204
Pulmonary function test decreased 116.18 18.94 58 22524 5674 42593079
Faeces soft 106.38 18.94 52 22530 4860 42593893
Forced vital capacity decreased 105.91 18.94 33 22549 907 42597846
Productive cough 100.34 18.94 130 22452 51437 42547316
Pulmonary fibrosis 100.27 18.94 95 22487 26586 42572167
Gastrointestinal disorder 99.30 18.94 123 22459 46530 42552223
Abnormal loss of weight 88.11 18.94 46 22536 4941 42593812
Pulmonary hypertension 86.81 18.94 83 22499 23486 42575267
Dyspnoea exertional 84.68 18.94 118 22464 50030 42548723
Drug ineffective 79.38 18.94 133 22449 630064 41968689
Lung neoplasm malignant 71.59 18.94 68 22514 19079 42579674
Abdominal pain upper 71.48 18.94 144 22438 82465 42516288
Oxygen saturation decreased 69.91 18.94 124 22458 64563 42534190
Drug-induced liver injury 63.02 18.94 89 22493 38184 42560569
Liver disorder 59.17 18.94 88 22494 39556 42559197
Toxicity to various agents 58.71 18.94 24 22558 229112 42369641
Chronic respiratory failure 58.69 18.94 25 22557 1697 42597056
Pneumomediastinum 58.66 18.94 30 22552 3086 42595667
Off label use 58.41 18.94 161 22421 638174 41960579
Drug interaction 57.83 18.94 35 22547 266964 42331789
Hepatic enzyme increased 55.00 18.94 92 22490 45692 42553061
Pulmonary embolism 54.58 18.94 163 22419 119449 42479304
Lung diffusion test decreased 51.94 18.94 19 22563 860 42597893
Disease progression 50.42 18.94 179 22403 143477 42455276
Interstitial lung disease 48.92 18.94 120 22462 78342 42520411
Constipation 46.87 18.94 190 22392 162101 42436652
Pneumonia 45.08 18.94 379 22203 421770 42176983
Abdominal discomfort 44.70 18.94 113 22469 75142 42523611
Vomiting 44.62 18.94 284 22298 289439 42309314
Flatulence 43.65 18.94 60 22522 25092 42573661
Epistaxis 37.27 18.94 98 22484 66728 42532025
Overdose 36.45 18.94 6 22576 105258 42493495
Pneumonia bacterial 36.00 18.94 43 22539 15649 42583104
General physical health deterioration 35.19 18.94 166 22416 151080 42447673
Product dose omission issue 35.14 18.94 19 22563 154346 42444407
Hypotension 34.48 18.94 52 22530 257579 42341174
Fatigue 34.43 18.94 367 22215 435274 42163479
Drug hypersensitivity 33.68 18.94 6 22576 99383 42499370
Hepatic function abnormal 33.33 18.94 80 22502 51487 42547266
Product use in unapproved indication 32.40 18.94 30 22552 184426 42414327
Completed suicide 32.30 18.94 6 22576 96459 42502294
Clinomania 32.21 18.94 7 22575 42 42598711
Confusional state 32.20 18.94 25 22557 167572 42431181
Haemoptysis 31.33 18.94 73 22509 46094 42552659
Pneumothorax spontaneous 31.23 18.94 13 22569 833 42597920
Liver function test increased 30.70 18.94 45 22537 19953 42578800
Acute kidney injury 30.29 18.94 97 22485 367240 42231513
Oxygen consumption increased 28.44 18.94 15 22567 1644 42597109
Stomatitis 27.23 18.94 73 22509 50256 42548497
Seizure 27.20 18.94 15 22567 120546 42478207
Post procedural pneumonia 26.58 18.94 7 22575 103 42598650
Colitis ischaemic 25.75 18.94 25 22557 7201 42591552
Product use issue 25.21 18.94 5 22577 76746 42522007
Small cell lung cancer 25.17 18.94 15 22567 2080 42596673
Metastases to central nervous system 24.78 18.94 29 22553 10326 42588427
Tachycardia 23.65 18.94 12 22570 101075 42497678
Mesenteric vein thrombosis 23.64 18.94 11 22571 921 42597832
Bradycardia 23.45 18.94 8 22574 85476 42513277
Diabetic ketoacidotic hyperglycaemic coma 22.87 18.94 7 22575 181 42598572
Somnolence 22.43 18.94 25 22557 141080 42457673
Pneumonitis 22.05 18.94 60 22522 41658 42557095
Systemic scleroderma 21.75 18.94 9 22573 568 42598185
Splenic vein thrombosis 21.67 18.94 9 22573 573 42598180
Inappropriate schedule of product administration 21.53 18.94 12 22570 95890 42502863
Dysgeusia 20.98 18.94 52 22530 34137 42564616
Pancytopenia 20.84 18.94 19 22563 117724 42481029
Hyperhidrosis 20.79 18.94 11 22571 90501 42508252
Colitis 20.76 18.94 63 22519 46509 42552244
Musculoskeletal stiffness 20.66 18.94 3 22579 57762 42540991
Asthma 20.59 18.94 4 22578 62310 42536443
Taste disorder 20.24 18.94 26 22556 10181 42588572
Fibrosis 20.13 18.94 15 22567 3015 42595738
Haemoglobin decreased 19.43 18.94 25 22557 132446 42466307
Acute coronary syndrome 19.36 18.94 31 22551 14834 42583919

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 2718.75 16.97 2489 32953 1137016 109416841
Death 944.45 16.97 1136 34306 697733 109856124
Malignant neoplasm progression 768.76 16.97 551 34891 174016 110379841
Decreased appetite 608.72 16.97 754 34688 475092 110078765
Weight decreased 418.71 16.97 624 34818 467433 110086424
Nausea 398.10 16.97 1072 34370 1234618 109319239
Pneumothorax 338.19 16.97 183 35259 35102 110518755
Dyspnoea 276.37 16.97 878 34564 1105994 109447863
Respiratory failure 213.58 16.97 302 35140 215030 110338827
Cough 204.32 16.97 454 34988 461187 110092670
Vomiting 202.20 16.97 695 34747 909980 109643877
Idiopathic pulmonary fibrosis 173.60 16.97 64 35378 4940 110548917
Lung transplant 148.67 16.97 58 35384 5228 110548629
Faeces soft 147.50 16.97 72 35370 11138 110542719
Dyspnoea exertional 143.78 16.97 172 35270 103888 110449969
Disease progression 142.03 16.97 269 35173 243765 110310092
Interstitial lung disease 135.94 16.97 194 35248 139140 110414717
Pulmonary hypertension 135.27 16.97 124 35318 55096 110498761
Forced vital capacity decreased 134.95 16.97 42 35400 1928 110551929
Pulmonary embolism 133.03 16.97 243 35199 214231 110339626
Flatulence 119.81 16.97 113 35329 52036 110501821
Constipation 115.53 16.97 312 35130 357474 110196383
Drug ineffective 114.93 16.97 195 35247 1520345 109033512
Pulmonary function test decreased 111.83 16.97 55 35387 8645 110545212
Oxygen saturation decreased 110.41 16.97 188 35254 156794 110397063
Productive cough 108.32 16.97 157 35285 114148 110439709
Drug hypersensitivity 96.68 16.97 15 35427 454075 110099782
Pneumomediastinum 96.51 16.97 42 35400 4994 110548863
Toxicity to various agents 93.44 16.97 20 35422 480535 110073322
Infusion related reaction 92.53 16.97 8 35434 381154 110172703
Abnormal loss of weight 92.15 16.97 51 35391 10206 110543651
Epistaxis 88.85 16.97 154 35288 130218 110423639
Drug-induced liver injury 88.67 16.97 147 35295 119920 110433937
Hepatic function abnormal 85.10 16.97 123 35319 89172 110464685
Liver disorder 79.22 16.97 154 35288 142089 110411768
Pneumonia 76.97 16.97 512 34930 876202 109677655
Joint swelling 73.71 16.97 25 35417 442820 110111037
Haemoptysis 73.47 16.97 102 35340 71252 110482605
Lung neoplasm malignant 71.43 16.97 70 35372 33772 110520085
Arthropathy 69.86 16.97 6 35436 287516 110266341
Chronic respiratory failure 69.78 16.97 31 35411 3872 110549985
Swelling 69.47 16.97 14 35428 351027 110202830
Confusional state 65.88 16.97 34 35408 468646 110085211
Therapeutic product effect decreased 65.59 16.97 3 35439 244313 110309544
Product use issue 64.74 16.97 11 35431 311684 110242173
Treatment failure 64.16 16.97 7 35435 277227 110276630
Systemic scleroderma 63.93 16.97 24 35418 1948 110551909
Maternal exposure during pregnancy 62.80 16.97 5 35437 254878 110298979
Wound 62.55 16.97 3 35439 234434 110319423
Gamma-glutamyltransferase increased 62.16 16.97 87 35355 61222 110492635
Completed suicide 61.89 16.97 4 35438 242377 110311480
Off label use 61.65 16.97 260 35182 1499925 109053932
Lung diffusion test decreased 60.36 16.97 22 35420 1643 110552214
Systemic lupus erythematosus 59.94 16.97 6 35436 254332 110299525
Abdominal pain upper 58.38 16.97 244 35198 348867 110204990
Musculoskeletal stiffness 57.83 16.97 10 35432 279812 110274045
Pericarditis 57.83 16.97 3 35439 219111 110334746
Hypersensitivity 57.23 16.97 29 35413 403969 110149888
Transaminases increased 57.03 16.97 85 35357 63305 110490552
Mucosal infection 56.96 16.97 16 35426 512 110553345
Pneumonitis 56.89 16.97 94 35348 76437 110477420
Asthma 53.85 16.97 8 35434 250283 110303574
Arthralgia 53.26 16.97 106 35336 779526 109774331
Hepatotoxicity 51.39 16.97 81 35361 63319 110490538
Pneumonia bacterial 51.14 16.97 52 35390 26209 110527648
Psoriatic arthropathy 50.97 16.97 3 35439 196758 110357099
Pemphigus 50.72 16.97 5 35437 214565 110339292
Pulmonary fibrosis 50.26 16.97 105 35337 101937 110451920
Metastases to central nervous system 49.65 16.97 48 35394 22769 110531088
Intestinal haemorrhage 48.73 16.97 30 35412 7311 110546546
Pain 48.01 16.97 152 35290 954803 109599054
Fatigue 46.25 16.97 593 34849 1215365 109338492
Injection site pain 45.23 16.97 3 35439 177919 110375938
Drug abuse 45.07 16.97 3 35439 177408 110376449
Injury 45.03 16.97 3 35439 177262 110376595
White blood cell count decreased 44.49 16.97 168 35274 229222 110324635
Helicobacter infection 43.61 16.97 4 35438 181873 110371984
Drug interaction 43.49 16.97 58 35384 500125 110053732
Fibromyalgia 43.10 16.97 3 35439 170906 110382951
Acute respiratory failure 42.51 16.97 82 35360 75178 110478679
Duodenal ulcer perforation 42.37 16.97 4 35438 177696 110376161
Pneumatosis intestinalis 42.23 16.97 29 35413 8500 110545357
Urticaria 42.07 16.97 25 35417 318832 110235025
Neutrophil count decreased 41.50 16.97 108 35334 120833 110433024
Overdose 41.00 16.97 12 35430 233782 110320075
Liver function test increased 40.02 16.97 88 35354 88460 110465397
Type 2 diabetes mellitus 39.69 16.97 5 35437 177227 110376630
Blister 39.28 16.97 12 35430 227364 110326493
Irritable bowel syndrome 38.35 16.97 4 35438 164211 110389646
Weight increased 38.18 16.97 47 35395 419597 110134260
Large intestine perforation 38.11 16.97 36 35406 16593 110537264
Pneumothorax spontaneous 37.60 16.97 16 35426 1801 110552056
Sinusitis 36.76 16.97 25 35417 296663 110257194
Wheezing 35.12 16.97 19 35423 255211 110298646
Hypoxia 34.95 16.97 106 35336 129409 110424448
Polyneuropathy 34.81 16.97 47 35395 31965 110521892
Oxygen consumption increased 34.63 16.97 22 35420 5663 110548194
Peripheral sensory neuropathy 34.26 16.97 34 35408 16646 110537211
Discomfort 34.19 16.97 13 35429 214694 110339163
Metastases to meninges 34.15 16.97 21 35421 5107 110548750
Muscle injury 34.02 16.97 3 35439 140804 110413053
Telangiectasia 33.85 16.97 15 35427 1862 110551995
Product dose omission issue 33.75 16.97 32 35410 321750 110232107
Mobility decreased 32.19 16.97 18 35424 237404 110316453
Colitis 31.70 16.97 88 35354 102235 110451622
Clinomania 31.63 16.97 7 35435 81 110553776
KL-6 increased 31.46 16.97 9 35433 308 110553549
Product use in unapproved indication 31.21 16.97 60 35382 447317 110106540
Diverticulitis 31.06 16.97 59 35383 53463 110500394
Bursitis 30.77 16.97 3 35439 129915 110423942
General physical health deterioration 30.00 16.97 236 35206 425059 110128798
Hypoaesthesia 29.85 16.97 34 35408 314189 110239668
Exercise tolerance decreased 29.34 16.97 27 35415 12040 110541817
Dehydration 29.23 16.97 171 35271 279340 110274517
Acute coronary syndrome 28.34 16.97 36 35406 23076 110530781
Cardiac failure 28.15 16.97 127 35315 187499 110366358
Hypophagia 28.09 16.97 56 35386 52570 110501287
Rash 27.88 16.97 152 35290 820812 109733045
Rheumatoid arthritis 27.83 16.97 33 35409 299580 110254277
Performance status decreased 27.52 16.97 21 35421 7245 110546612
Physical deconditioning 27.49 16.97 16 35426 3521 110550336
Post procedural pneumonia 27.13 16.97 7 35435 161 110553696
Diarrhoea haemorrhagic 26.93 16.97 29 35413 15610 110538247
Alanine aminotransferase increased 26.53 16.97 123 35319 183650 110370207
Nephrotic syndrome 26.23 16.97 27 35415 13804 110540053
Bradycardia 25.46 16.97 9 35433 155508 110398349
Blood cholesterol increased 25.06 16.97 14 35428 184771 110369086
Ageusia 24.72 16.97 31 35411 19614 110534243
Abdominal pain 24.64 16.97 262 35180 512727 110041130
Microstomia 24.48 16.97 5 35437 38 110553819
COVID-19 24.38 16.97 148 35294 244912 110308945
Aspartate aminotransferase increased 23.79 16.97 108 35334 159828 110394029
Aortic aneurysm 23.77 16.97 22 35420 9882 110543975
Diabetic ketoacidotic hyperglycaemic coma 23.61 16.97 7 35435 272 110553585
Anti-neutrophil cytoplasmic antibody positive vasculitis 23.53 16.97 17 35425 5400 110548457
Idiopathic interstitial pneumonia 23.45 16.97 9 35433 776 110553081
Agitation 23.43 16.97 4 35438 113047 110440810
Pain in extremity 23.39 16.97 79 35363 487039 110066818
Small cell lung cancer 23.33 16.97 14 35428 3258 110550599
Migraine 23.28 16.97 13 35429 171639 110382218
Night sweats 23.26 16.97 7 35435 133976 110419881
Depressed level of consciousness 23.21 16.97 4 35438 112274 110441583
Stomatitis 23.07 16.97 157 35285 270085 110283772
Coma 22.68 16.97 5 35437 117864 110435993
Pulmonary function test abnormal 22.42 16.97 16 35426 4984 110548873
Peripheral swelling 21.89 16.97 62 35380 403972 110149885
Anaphylactic reaction 21.69 16.97 5 35437 114295 110439562
Pulmonary arterial hypertension 21.55 16.97 38 35404 32530 110521327
Malignant neoplasm of pleura 21.36 16.97 6 35436 192 110553665
Intentional product use issue 21.26 16.97 29 35413 247877 110305980
Intentional product misuse 21.23 16.97 8 35434 132896 110420961
Lung adenocarcinoma 20.64 16.97 20 35422 9511 110544346
Inflammation 20.51 16.97 19 35423 193219 110360638
Gait inability 20.50 16.97 9 35433 136367 110417490
Inappropriate schedule of product administration 20.48 16.97 21 35421 203616 110350241
Injection site erythema 20.27 16.97 3 35439 94173 110459684
Hypotension 20.03 16.97 93 35349 523756 110030101
Tachycardia 19.96 16.97 26 35416 226619 110327238
HRD gene mutation assay positive 19.88 16.97 4 35438 28 110553829
Psoriasis 19.87 16.97 10 35432 139983 110413874
Epilepsy 19.79 16.97 4 35438 100205 110453652
Ill-defined disorder 19.71 16.97 13 35429 156840 110397017
Pruritus 19.54 16.97 108 35334 581452 109972405
Dermatitis acneiform 19.20 16.97 22 35420 12673 110541184
Cancer with a high tumour mutational burden 19.09 16.97 4 35438 35 110553822
Somnolence 18.94 16.97 42 35400 297407 110256450
Ischaemic stroke 18.63 16.97 41 35401 41222 110512635
Dysgeusia 18.61 16.97 57 35385 69928 110483929
Cerebral infarction 18.50 16.97 47 35395 51791 110502066
Fibrosis 18.39 16.97 17 35425 7625 110546232
Wrong technique in product usage process 18.30 16.97 3 35439 87345 110466512
Obstruction gastric 18.07 16.97 10 35432 2001 110551856
Neutropenic sepsis 17.97 16.97 34 35408 30712 110523145
Adenosquamous cell lung cancer 17.86 16.97 4 35438 49 110553808
Non-small cell lung cancer 17.84 16.97 17 35425 7918 110545939
Dairy intolerance 17.66 16.97 6 35436 364 110553493
Sciatica 17.61 16.97 4 35438 92395 110461462
Swelling face 17.59 16.97 4 35438 92317 110461540
Gastrooesophageal reflux disease 17.46 16.97 108 35334 179868 110373989
Muscle spasms 17.12 16.97 40 35402 278117 110275740

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX09 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:38637 tyrosine kinase inhibitor
CHEBI has role CHEBI:48422 angiogenesis inhibitor
CHEBI has role CHEBI:63457 fibroblast growth factor receptor antagonist
CHEBI has role CHEBI:65207 vascular endothelial growth factor receptor antagonist
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

L01EX Other protein kinase inhibitors 21 drugs
avapritinibcabozantinibcapivasertibentrectinibgilteritiniblarotrectiniblenvatinibmidostaurinpazopanibpexidartinibpralsetinibquizartinib show all 21 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Interstitial fibrosis indication 125565008
Systemic sclerosis associated interstitial lung disease indication 233703007 DOID:3082
Non-small cell lung cancer indication 254637007 DOID:3908
Idiopathic pulmonary fibrosis indication 700250006 DOID:0050156




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.97 acidic
pKa2 7.77 Basic
pKa3 3.25 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL 10154990 Jan. 8, 2026 USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL 10154990 Jan. 8, 2026 USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Sept. 6, 2026 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL Sept. 6, 2026 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
EQ 100MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL March 6, 2027 PEDIATRIC EXCLUSIVITY
EQ 150MG BASE OFEV BOEHRINGER INGELHEIM N205832 Oct. 15, 2014 RX CAPSULE ORAL March 6, 2027 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.82 CHEMBL CHEMBL
Fibroblast growth factor receptor 2 Kinase INHIBITOR Kd 6.46 CHEMBL CHEMBL
Fibroblast growth factor receptor 3 Kinase INHIBITOR Kd 7.03 CHEMBL CHEMBL
Fibroblast growth factor receptor 4 Kinase INHIBITOR Kd 5.74 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 6.98 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR IC50 8.30 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 8.30 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 7.75 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Fibroblast growth factor receptor 1 Kinase INHIBITOR IC50 7.42 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Tyrosine-protein kinase Lck Kinase Kd 8.21 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 7.10 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 6.20 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 5.54 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 9.38 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 8.02 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.32 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 7.19 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 6.59 CHEMBL
Cyclin-dependent kinase 2 Kinase Kd 5.85 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 7.21 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 6.54 CHEMBL
Insulin receptor Kinase AGONIST Kd 7.62 CHEMBL
Death-associated protein kinase 3 Kinase Kd 5.68 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 5.23 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 6.20 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.68 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.28 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 8.32 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 6.57 CHEMBL
Death-associated protein kinase 2 Kinase Kd 5.49 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 8.35 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 7.85 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.40 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.85 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 7.20 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 5.85 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 6.70 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.03 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 7.24 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 7.06 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 6.85 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 5.44 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.06 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 7.14 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 7.28 CHEMBL
Aurora kinase C Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 7.74 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 7.66 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.13 CHEMBL
Protein kinase C theta type Kinase Kd 5.26 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 6.96 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.28 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 6.64 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.52 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 7.51 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.07 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 8.66 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.57 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 8.06 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 6.12 CHEMBL
Glycogen synthase kinase-3 beta Kinase Kd 7.08 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.26 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 5.66 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 7.68 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 8.05 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.80 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 6.70 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.29 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 7.74 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 6.04 CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 6.11 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1 Kinase Kd 6.20 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 6.59 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 7.92 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.96 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.21 CHEMBL
Activin receptor type-1B Kinase Kd 5.31 CHEMBL
Serine/threonine-protein kinase receptor R3 Kinase Kd 5.38 CHEMBL
Activin receptor type-1 Kinase Kd 6.22 CHEMBL
3-phosphoinositide-dependent protein kinase 1 Kinase Kd 5.55 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 8 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 7.38 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 6.68 CHEMBL
Tyrosine-protein kinase ZAP-70 Kinase Kd 5.46 CHEMBL
Glycogen synthase kinase-3 alpha Kinase Kd 6.37 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 6.51 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 7.92 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 7.72 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 5.31 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.52 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.11 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 7.42 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 6.64 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 7.68 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.68 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 7.43 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 6.54 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 6.68 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 7.03 CHEMBL
Cyclin-dependent kinase 18 Kinase Kd 6.29 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 6.33 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 7.31 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Kinase Kd 7.77 CHEMBL
Myosin light chain kinase family member 4 Kinase Kd 6.36 CHEMBL
Wee1-like protein kinase Kinase Kd 5.54 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 7.09 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 7.64 CHEMBL
Casein kinase I isoform delta Kinase Kd 5.89 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.66 CHEMBL
NT-3 growth factor receptor Kinase Kd 7.49 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 6.07 CHEMBL
Casein kinase II subunit alpha Kinase Kd 5.12 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 6.05 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B Kinase Kd 5.80 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.77 CHEMBL
Serine/threonine-protein kinase STK11 Kinase Kd 7.74 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.68 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 8.31 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 7.31 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 5.70 CHEMBL
Insulin receptor-related protein Kinase Kd 7.68 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 5.28 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 7.44 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.55 CHEMBL
SRSF protein kinase 1 Kinase Kd 7.43 CHEMBL
SRSF protein kinase 2 Kinase Kd 7.44 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 5.96 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-2 Kinase Kd 7.08 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.38 CHEMBL
Serine/threonine-protein kinase LATS1 Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase LATS2 Kinase Kd 6.42 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 6.82 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.46 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 5.89 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 6.80 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.54 CHEMBL
Aurora kinase B Kinase Kd 6.38 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.42 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 7.25 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.82 CHEMBL
Serine/threonine-protein kinase MARK1 Kinase Kd 5.85 CHEMBL
MAP/microtubule affinity-regulating kinase 4 Kinase Kd 5.70 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 5.43 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 8.07 CHEMBL
Calcium/calmodulin-dependent protein kinase type IV Kinase Kd 5.43 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 6.66 CHEMBL
Mitogen-activated protein kinase kinase kinase 10 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 6.15 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 6.96 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.23 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.27 CHEMBL
Myosin-IIIb Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase PAK 2 Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.52 CHEMBL
Cyclin-dependent kinase 3 Kinase Kd 6.84 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 6.17 CHEMBL
TGF-beta receptor type-1 Kinase Kd 5.38 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.92 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5.60 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 6.14 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.19 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.62 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 5.92 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase Kd 5.43 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 6.74 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 6.21 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 6.54 CHEMBL
Misshapen-like kinase 1 Kinase Kd 7.09 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.82 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 6.09 CHEMBL
Cyclin-dependent kinase 4 Kinase Kd 6.80 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 5.70 CHEMBL
Rhodopsin kinase Kinase Kd 6 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 7.77 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 5.92 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 6.10 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 6.07 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase ICK Kinase Kd 5.77 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha Kinase Kd 5.35 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 6.92 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 8.03 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 7.47 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 5.34 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.03 CHEMBL
SRSF protein kinase 3 Kinase Kd 7.92 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 6.28 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 8.39 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 6.47 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 6.42 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 7.22 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 8.28 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.85 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 6.36 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.09 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase PRP4 homolog Kinase Kd 8.08 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase Sgk3 Kinase Kd 6 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.74 CHEMBL
Myosin light chain kinase 3 Kinase Kd 6.96 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.43 CHEMBL
cGMP-dependent protein kinase 1 Kinase Kd 7.85 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 6.41 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 8.09 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 8.59 CHEMBL
Multidrug resistance protein 1 Transporter EC50 6.56 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 8 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 8.57 CHEMBL
Breakpoint cluster region protein Kinase Kd 6.52 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 6.24 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 5.92 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 7.89 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 8.44 CHEMBL

External reference:

IDSource
G6HRD2P839 UNII
D10396 KEGG_DRUG
4033814 VUID
N0000191096 NUI
656247-18-6 SECONDARY_CAS_RN
4033814 VANDF
C2930789 UMLSCUI
CHEBI:85164 CHEBI
CHEMBL502835 ChEMBL_ID
135423438 PUBCHEM_CID
DB09079 DRUGBANK_ID
CHEMBL3039504 ChEMBL_ID
9229 INN_ID
C530716 MESH_SUPPLEMENTAL_RECORD_UI
5936 IUPHAR_LIGAND_ID
1592736 RXNORM
229920 MMSL
30617 MMSL
402647 MMSL
d08301 MMSL
015720 NDDF
015723 NDDF
712494002 SNOMEDCT_US
715613009 SNOMEDCT_US
863993005 SNOMEDCT_US
XIN PDB_CHEM_ID
G6HRD2P839 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ofev HUMAN PRESCRIPTION DRUG LABEL 1 0597-0143 CAPSULE 100 mg ORAL NDA 30 sections
Ofev HUMAN PRESCRIPTION DRUG LABEL 1 0597-0145 CAPSULE 150 mg ORAL NDA 30 sections
nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 0781-2492 CAPSULE 100 mg ORAL ANDA 29 sections
nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 0781-2495 CAPSULE 150 mg ORAL ANDA 29 sections
Nintedanib Human Prescription Drug Label 1 42799-972 CAPSULE 100 mg ORAL ANDA 27 sections
Nintedanib Human Prescription Drug Label 1 42799-973 CAPSULE 150 mg ORAL ANDA 27 sections
nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 42806-568 CAPSULE 150 mg ORAL ANDA 29 sections
nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 42806-569 CAPSULE 100 mg ORAL ANDA 29 sections
Nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 43598-147 CAPSULE 150 mg ORAL ANDA 25 sections
Nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 43598-148 CAPSULE 100 mg ORAL ANDA 25 sections
Nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 51407-984 CAPSULE 100 mg ORAL ANDA 27 sections
Nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 51407-985 CAPSULE 150 mg ORAL ANDA 27 sections
Nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 60505-4818 CAPSULE 100 mg ORAL ANDA 27 sections
Nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 60505-4819 CAPSULE 150 mg ORAL ANDA 27 sections
nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 68462-802 CAPSULE 100 mg ORAL ANDA 27 sections
nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 68462-803 CAPSULE 150 mg ORAL ANDA 27 sections
Nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 69097-639 CAPSULE 150 mg ORAL ANDA 24 sections
Nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 69097-641 CAPSULE 100 mg ORAL ANDA 24 sections
nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 73190-096 CAPSULE 100 mg ORAL ANDA 27 sections
nintedanib HUMAN PRESCRIPTION DRUG LABEL 1 73190-097 CAPSULE 150 mg ORAL ANDA 27 sections
Nintedanib Capsules, 100 mg and 150 mg HUMAN PRESCRIPTION DRUG LABEL 1 76282-786 CAPSULE 100 mg ORAL ANDA 24 sections
Nintedanib Capsules, 100 mg and 150 mg HUMAN PRESCRIPTION DRUG LABEL 1 76282-787 CAPSULE 150 mg ORAL ANDA 24 sections